Revenue growth should surely be returning after that little 2021 slump? Look forward to the Appendix 4C. Commiserations to long-term holders. I appreciate I am only just joining the holders at good levels by comparison. After been invested in many bio-techs with quality products and yet poor financial returns I appreciate the frustration. Still fundamentally a very promising company if they return to those growing revenues out of the grips of COVID.
Ann: Osteopore collaborates with Singular Health Group, page-11
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
